These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12761741)

  • 1. Small molecules as inhibitors of cyclin-dependent kinases.
    Huwe A; Mazitschek R; Giannis A
    Angew Chem Int Ed Engl; 2003 May; 42(19):2122-38. PubMed ID: 12761741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.
    Song Y; Kesuma D; Wang J; Deng Y; Duan J; Wang JH; Qi RZ
    Biochem Biophys Res Commun; 2004 Apr; 317(1):128-32. PubMed ID: 15047157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase inhibitors.
    Fischer PM; Endicott J; Meijer L
    Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-cycle molecules in mesothelioma: an overview.
    Spugnini EP; Campioni M; D'Avino A; Caruso G; Citro G; Baldi A
    J Exp Clin Cancer Res; 2007 Dec; 26(4):443-9. PubMed ID: 18365537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cell cycle, cyclin-dependent kinases, and viral infections: new horizons and unexpected connections.
    Schang LM
    Prog Cell Cycle Res; 2003; 5():103-24. PubMed ID: 14593705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing inhibitors of cyclin-dependent kinases.
    Hardcastle IR; Golding BT; Griffin RJ
    Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.
    Andrés V
    Cardiovasc Res; 2004 Jul; 63(1):11-21. PubMed ID: 15194457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM
    Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different classes of novel Pfmrk specific inhibitors.
    Bhattacharjee AK; Geyer JA; Woodard CL; Kathcart AK; Nichols DA; Prigge ST; Li Z; Mott BT; Waters NC
    J Med Chem; 2004 Oct; 47(22):5418-26. PubMed ID: 15481979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclins and related kinases in cancer cells.
    Malumbres M
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.
    Caligiuri M; Becker F; Murthi K; Kaplan F; Dedier S; Kaufmann C; Machl A; Zybarth G; Richard J; Bockovich N; Kluge A; Kley N
    Chem Biol; 2005 Oct; 12(10):1103-15. PubMed ID: 16242653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinases: bridging their structure and function through computations.
    De Vivo M; Bottegoni G; Berteotti A; Recanatini M; Gervasio FL; Cavalli A
    Future Med Chem; 2011 Sep; 3(12):1551-9. PubMed ID: 21882947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
    Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
    J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
    Anderson M; Andrews DM; Barker AJ; Brassington CA; Breed J; Byth KF; Culshaw JD; Finlay MR; Fisher E; McMiken HH; Green CP; Heaton DW; Nash IA; Newcombe NJ; Oakes SE; Pauptit RA; Roberts A; Stanway JJ; Thomas AP; Tucker JA; Walker M; Weir HM
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5487-92. PubMed ID: 18815031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
    Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
    Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.